Compare Cytokinetics Inc (CYTK) vs FedEx Corporation (FDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs FedEx Corporation — how do they compare? Cytokinetics Inc trades at $82.35 (market cap $11.12B), while FedEx Corporation trades at $317.46 (market cap $74.84B). The key difference: FedEx Corporation is far larger — about 6.7× Cytokinetics Inc's market cap, and FedEx Corporation pays a 1.56% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | FDX | |
|---|---|---|
Market Cap | $11.12B | $74.84B |
Sector | Technology | Industrials |
52-Week High | $87.26 | $338.75 |
52-Week Low | $33.23 | $174.81 |
Enterprise Value | $11.59B | $104.47B |
Dividend Yield | — | 1.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
FedEx (FDX) trades at $313.74, down 0.3% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $6.31, beating expectations, and is executing strategic moves like the $1.4 billion sale of its supply chain unit to CMA CGM. Valuation ratios appear reasonable with a P/E of 16.91 and P/S of 0.79, while analyst consensus remains positive with a $358.80 price target.
The outlook is mixed; cost-cutting initiatives and debt reduction via a $4.15 billion tender offer support fundamentals, but weak shipping demand and margin pressures pose risks. Upside depends on margin recovery from DRIVE and Network 2.0 programs, though competitive threats from Amazon logistics and economic sensitivity warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →
